Skip to content
value.today

Tokai Pharmaceuticals Inc

Total raised
$32 M
3 rounds on record
Latest round
$20 M
May 2013
First round on record
May 2009
Today
Went public
See the company page

Tokai Pharmaceuticals Inc is listed today as Eledon Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Tokai Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$50 MPrivate placement after listing$50 to $250 million

Tokai Pharmaceuticals Inc: Private sale, May 2024

Investors in this round

24 investors had bought by the notice of May 23, 2024: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,617,174
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Smith · Executive Officer
  • David-Alexandre Gros · Executive Officer, Director
  • Paul Little · Executive Officer
  • Steven Perrin · Executive Officer, Director
  • Allan Kirk · Director
  • James Robinson · Director
  • Jan Hillson · Director
  • John McBride · Director
  • June Lee · Director
  • Keith Katkin · Director
  • Walter Ogier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Leerink Partners LLC (CRD 39011) · Boston, MassachusettsSold in all US states, and outside the US
  • Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, FloridaSold in CA, FL, ID, MA, ND, NV, NY, VA

Remarks in the notice

  • On the amounts: “$49,999,010.48 of common stock and pre-funded warrants sold; plus $7,989.52 assuming exercise of all pre-funded warrants.”

Signed by Paul Little, Chief Financial Officer. Newest notice filed May 23, 2024. Read the notice at the SEC.

equity, optionsSEC
May 2023$35 MPrivate placement after listing$10 to $50 million

Tokai Pharmaceuticals Inc: Private sale, May 2023

Investors in this round

38 investors had bought by the notice of May 22, 2023: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$35 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$1,227,961
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Smith · Executive Officer
  • David-Alexandre Gros · Executive Officer, Director
  • Paul Little · Executive Officer
  • Steven Perrin · Executive Officer, Director
  • Gary Lyons · Director
  • Jan Hillson · Director
  • John McBride · Director
  • June Lee · Director
  • Keith Katkin · Director
  • Walter Ogier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, FloridaSold in CA, DE, FL, ID, NH, NJ, NV, NY, TX, and outside the US
  • SVB Securities LLC (CRD 39011) · Boston, MassachusettsSold in all US states, and outside the US

Remarks in the notice

  • On the amounts: “$35M of common stock sold in initial closing; plus $45M assuming exercise of all common warrants issued in initial closing; and $46.7M and $58.3M upon sale of common stock issuable in 2nd and 3rd closings, upon the satisfaction of specified conditions.”

Signed by Paul Little, Chief Financial Officer. Newest notice filed May 22, 2023. Read the notice at the SEC.

equity, optionsSEC
Sep 2020$108 MPrivate placement after listing$50 to $250 million

Tokai Pharmaceuticals Inc: Private sale, Sep 2020

Investors in this round

35 investors had bought by the notice of Sep 25, 2020: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$108 M of $108 M offered
Smallest investment taken
$498
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,123,597
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David-Alexandre Gros · Executive Officer, Director
  • Jon N. Kuwahara · Executive Officer
  • Gary A. Lyons · Director
  • John A. McBride · Director
  • Keith A. Katkin · Director
  • Steven N. Perrin · Director
  • Walter A. Ogier · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Capital Markets, Inc. (CRD 15768) · Boca Raton, FloridaSold in AL, CA, FL, NV, NY, TX, and outside the US
  • SVB Leerink LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Signed by David-Alexandre Gros, Chief Executive Officer. Newest notice filed Sep 25, 2020. Read the notice at the SEC.

equitySEC
May 2013$20 MNo. 3$10 to $50 million

Tokai Pharmaceuticals Inc: Raise no. 3, May 2013

Investors in this round

19 investors had bought by the notice of May 15, 2013: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $36 M offered; $16 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jodie P. Morrison · Executive Officer
  • Campbell A. Murray · Director
  • David A. Kessler · Director
  • Joseph A. Yanchik, III · Director
  • Reinhard J. Ambros · Director
  • Seth L. Harrison · Director
  • Timothy J. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jodie P. Morrison, Chief Executive Officer. Newest notice filed May 15, 2013. Read the notice at the SEC.

equitySEC
Sep 2011$2 MNo. 2Under $2 million

Tokai Pharmaceuticals Inc: Raise no. 2, Sep 2011

Investors in this round

6 investors had bought by the notice of Sep 20, 2011: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $23 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Seth L. Harrison · Executive Officer, Director
  • Campbell A. Murray · Director
  • David A. Kessler · Director
  • Joseph A. Yanchik, III · Director
  • Reinhard A. Ambros · Director
  • Timothy A. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cindy Driscoll, Director of Finance and Administration. Newest notice filed Sep 20, 2011. Read the notice at the SEC.

equitySEC
May 2009$10 MNo. 1$10 to $50 million

Tokai Pharmaceuticals Inc: Raise no. 1, May 2009

Investors in this round

10 investors had bought by the notice of May 6, 2009: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $22 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Scott Chappel · Executive Officer
  • Seth L. Harrison · Executive Officer, Director
  • Campbell Murray · Director
  • David Kessler · Director
  • Joseph A. Yanchik, III · Director
  • Reinhard Ambros · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Seth L. Harrison, Chief Executive Officer. Newest notice filed May 6, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tokai Pharmaceuticals Inc had no revenue when it filed its newest notice of a funding round (May 2024).

    SEC Form D (revenue range) · May 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2024

Products and services#

No products or services of Tokai Pharmaceuticals Inc are on record.

Investors#

No investor of Tokai Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Eledon Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tokai Pharmaceuticals Inc
NameRoleNamed in
Bryan SmithExecutive officerMay 2024
David-Alexandre GrosExecutive officerMay 2024
Paul LittleExecutive officerMay 2024
Steven PerrinExecutive officerMay 2024
Jon N. KuwaharaExecutive officerSep 2020
Jodie P. MorrisonExecutive officerMay 2013
Seth L. HarrisonExecutive officerSep 2011
Scott ChappelExecutive officerMay 2009
Allan KirkDirectorMay 2024
David-Alexandre GrosDirectorMay 2024
James RobinsonDirectorMay 2024
Jan HillsonDirectorMay 2024
John McBrideDirectorMay 2024
June LeeDirectorMay 2024
Keith KatkinDirectorMay 2024
Steven PerrinDirectorMay 2024
Walter OgierDirectorMay 2024
Gary LyonsDirectorMay 2023
Gary A. LyonsDirectorSep 2020
John A. McBrideDirectorSep 2020
Keith A. KatkinDirectorSep 2020
Steven N. PerrinDirectorSep 2020
Walter A. OgierDirectorSep 2020
Campbell A. MurrayDirectorMay 2013
David A. KesslerDirectorMay 2013
Joseph A. Yanchik, IIIDirectorMay 2013
Reinhard J. AmbrosDirectorMay 2013
Seth L. HarrisonDirectorMay 2013
Timothy J. BarberichDirectorMay 2013
Reinhard A. AmbrosDirectorSep 2011
Timothy A. BarberichDirectorSep 2011
Campbell MurrayDirectorMay 2009
David KesslerDirectorMay 2009
Reinhard AmbrosDirectorMay 2009

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.